Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5195MR)

This product GTTS-WQ5195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Mus musculus
RefSeq	NM_001185099.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	933
UniProt ID	P20273

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5195MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4150MR	IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BI-754091
GTTS-WQ7164MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	FMC63 scFv-28Z CAR
GTTS-WQ13981MR	IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	REGN-3470-3471-3479
GTTS-WQ13746MR	IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	REGN 1500
GTTS-WQ5619MR	IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CDP791
GTTS-WQ4901MR	IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	BYM338
GTTS-WQ8506MR	IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	hu1124
GTTS-WQ9624MR	IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	JNJ-63723283

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST